Sandoz Rivastigmine 1.5 mg (Rivastigmine (Rivastigmine Hydrogen Tartrate) CAPSULE) 1.5 MG

Sandoz Rivastigmine 1.5 mg capsules are a prescription medication used to manage symptoms of Alzheimer's and Parkinson's disease. This oral treatment may help improve cognitive function and daily living activities.

Strength

1.5 MG

Pack Size

56/100

Manufacturer / TM Owner

SANDOZ CANADA INCORPORATED

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Rivastigmine is commonly used to treat symptoms associated with Alzheimer's disease and Parkinson's disease dementia. It works by increasing certain chemicals in the brain that are important for cognitive function. People often ask, 'What is Rivastigmine used for?' and the answer is that it helps manage memory loss, confusion, and other cognitive impairments.

Side Effects

Common effects of Rivastigmine may include nausea, vomiting, dizziness, and loss of appetite. Some users also report headaches, fatigue, and stomach pain. These effects can vary in intensity and duration depending on the individual.

Precautions & Warnings

Rivastigmine should be handled with care, especially for those with a history of stomach ulcers or severe nausea. It is important to follow the advice of a healthcare provider regarding its use. Always store the medication in a safe place, away from children and pets.

Avoid Interactions

Rivastigmine may interact with other medications, including those that affect the central nervous system. It is important to inform your healthcare provider about all medications you are taking. Alcohol and certain dietary supplements may also interact with Rivastigmine.

Frequently Asked Questions

Rivastigmine is used to manage symptoms of Alzheimer's disease and Parkinson's disease dementia, helping to improve cognitive function and daily living activities.

Rivastigmine is typically taken orally, with or without food, as directed by a healthcare provider.

Common side effects include nausea, vomiting, dizziness, and loss of appetite. Some users may also experience headaches and fatigue.

Rivastigmine may interact with other medications, so it is important to consult a healthcare provider before combining it with other treatments.

Long-term use of Rivastigmine should be monitored by a healthcare provider to ensure its continued safety and effectiveness.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.